Replies to post #210920 on Biotech Values

[DewDiligence]

FDA approves Brigatinib for second-line ALK+ NSCLC:

https://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm555841.htm

This is an accelerated approval based on a phase-2 trial in which ORR was the primary endpoint (https://www.clinicaltrials.gov/ct2/show/NCT02094573 ).